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Abstract: 
In patients who receive transplantation for alcohol liver disease, obesity and metabolic syndrome are highly 
prevalent after transplantation and both contribute to a significant proportion of cardiovascular complications, 
late morbidity and mortality in this population. Although immunosuppressive medications have been 
hypothesised to explain some of these post-liver-transplantation (LT) metabolic complications, they cannot be 
considered the sole cause of obesity and metabolic syndrome, and the high prevalence of these illnesses remains 
unexplained. Given the significant overlap between the neurobiological, psychiatric and psychological factors 
that underlie alcohol addiction and reward-related behavioural dyscontrol disorders such as food addiction (FA), 
we hypothesised that the high prevalence of obesity and metabolic syndrome reported in patients who receive 
transplantation for alcohol liver disease could be explained at least partially by a switch in some individuals from 
a previous alcohol addiction to post-transplantation FA (i.e., addiction transfer = addiction switch). In our 
integrative model, we also speculate that an increased prevalence of FA or alcohol addiction may occur in 
patients with both specific psychobiological profiles and shared risk factors. We further hypothesise that in the 
subpopulation of patients who develop either alcohol addiction or FA after LT, those with high insight with 
regard to the consequences of alcohol use could be at higher risk for FA, whereas those with low insight could 
be at higher risk for alcohol addiction. We discuss here evidence for and against this hypothesis and discuss 
which patients could be more vulnerable to these two addictions after LT. Because it will not be either possible 
or ethical to test some of our hypotheses in humans, future studies should test these hypotheses using a 
translational strategy, using both clinical and preclinical approaches. If our hypotheses could account for the 
significant increase in obesity and metabolic syndrome after LT, this would lead to new avenues for research and 
preventive as well as therapeutic interventions for alcohol-related LT patients. All patients with previous or 
current alcohol addiction should be systematically screened for FA and followed up for subsequent risk of 
obesity and metabolic syndrome. Such strategies might be effective in improving survival, outcomes and quality 
of life after LT and also in the overall population of patients with alcohol addiction. By determining common 
risk factors for both alcohol addiction and FA using a translational approach, our model could help to find novel 
psychopharmacological and psychological strategies that might be effective in both FA and alcohol addiction. 
Keywords:liver transplantation; liver disease; food addiction; obesity; binge eating disorder; compulsive eating 
behaviour; alcohol dependence; alcohol addiction; alcohol abuse; alcohol use disorder; alcoholism; addiction 
transfer; switch; insight; psychiatric disorders. 
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INTRODUCTION 
Alcohol use disorders are defined by a cluster of cognitive, behavioural, and physiological symptoms 
that indicate persistent use of a substance despite significant substance-related problems [1]. These disorders are 
a major public health problem worldwide, with a lifetime prevalence rate in the United States estimated at 17.8% 
(0.5) and 12.5% (0.4) for alcohol abuse and dependence [2], thereby representing a health, social and economical 
burden to western societies [3]. Approximately 3.8% of all global deaths and 4.6% of global disability-adjusted 
life-years are attributable to alcohol [3]. In France, in 2009, 36,500 deaths in men were attributable to alcohol 
(13% of total mortality) versus 12,500 in women (5% of total mortality) [4]. One of the somatic consequences of 
protracted alcohol addiction is liver cirrhosis or liver failure, for which liver transplantation (LT) has 
progressively become the best, and sometimes the only therapeutic alternative for patients with end-stage liver 
failure [5]. 
 However, the success rate of LT in patients suffering from alcohol addiction remains relatively poor. It 
is critical to better identify the factors that contribute to poorer post-transplant outcomes in former alcohol 
addicts not only because alcohol use disorders are currently the leading cause for LT [6] but also because these 
factors lead, when untreated, to lower quality of life and lower survival rates [7]. This is a major public health 
issue not only for these patients but also because of the economic and social costs associated with liver 
transplantation and the limited number of organ donors, which prevents other patients with potentially better 
outcomes from benefiting from this treatment [5].  
 Obesity and metabolic syndrome are among the main factors that contribute to a significant part of 
cardiovascular complications and late morbidity and mortality after LT [8]. Some factors such as use of 
immunosuppressive medications, donor characteristics (e.g., body mass index), and pre-transplant nutritional 
and metabolic status have been hypothesised to account for some of these post-LT metabolic complications (see 
for review [9]). However, these hypotheses cannot explain why and how patients with a pre-transplant alcohol 
use disorder are at higher risk than other liver-transplanted patients for developing post-transplant metabolic 
syndrome [8,10] and obesity [11]. According to a study conducted by Anastácio et al. in 148 liver transplanted 
patients with a mean follow-up of 3.5 years [10], prevalence for metabolic syndrome was 84% higher in patient 
transplanted for an alcohol liver disease when compared to patients transplanted for a non-alcohol liver disease 
(prevalence rate for metabolic syndrome were respectively 71.7% and 38.9%; OR=3.88; 95% CI=1.43-10.51; 
p<0.001). 
 The elevated rate of metabolic syndrome observed in patients with alcohol use disorder after LT is all 
the more surprising given that the risk of relapsing to alcohol use after LT, a classic risk factor for post-LT 
metabolic complications, is lower in these patients than in control populations that are treated for alcohol abuse 
[12]. During the five years following LT, one out of four and one out of eight patients, respectively, will relapse 
to any alcohol use or to heavy alcohol use [6], whereas in primary care, more than four patients out of five will 
relapse to alcohol use in any given 18-month period [13]. We currently don’t know whether it is the amount of 
alcohol intake an/or the duration of alcohol intake that are associated with higher risk for post-transplant 
metabolic complications, and we alsolack an understanding of why patients who receive transplantation for 
alcohol liver disease show both an increased risk of metabolic syndrome and obesity and a lower risk of relapse 
to alcohol addiction after LT. 
 Although excessive and compulsive food intake may be a prominent contributor to the high incidence 
of overweight and obesity after LT and in patients with a preoperative alcohol use disorder, data on food intake 
in patients who receive transplantation for an alcohol use disorder are very scarce [9]. Only Correia et al. 
mentioned that “non-healthy habits’ might be a risk factor for post-transplant obesity [14], but no studies have so 
far explicitly assessed whether an increased propensity to develop food addiction could be a potential risk factor 
for later obesity or metabolic syndrome in patients who receive transplantation for an alcohol use disorder. Food 
addiction, a concept that has been recently proposed by applying the DSM-IV-TR criteria for substance 
dependence to eating behaviour in order to describe patients who exhibit eating patterns that are similar to the 
behaviours classically seen in drug-addicted patients [15–17], is indeed strongly associated with obesity [18,19], 
and it has been hypothesised to play a major role in the recent increase in obesity prevalence in the overall 
population [20].  
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 Finally, it is noteworthy that studies in the field of bariatric surgery have demonstrated that when 
previous eating behaviour was restricted by bariatric surgery, alcohol use disorders increased [21]. 
 
HYPOTHESIS 
Our main hypothesis is that the high rates of obesity and metabolic syndrome reported in post-LT 
patients could be attributable to a switch from a previous alcohol addiction to a post-LT food addiction (i.e., 
addiction transfer = addiction switch) in a subpopulation of vulnerable individuals who share certain specific 
psychobiological risk factors and who also share coping strategies under the peer and moral pressure associated 
with LT. More specifically, we hypothesise that low insight with regard to the somatic and psychological 
consequences of alcohol addiction could predict higher risk of alcohol relapse after LT whereas high insight 
could predict higher risk of developing a food addiction after LT. 
 We will present a correlational model in which food addiction could partially account for the variance 
in obesity and metabolic syndrome observed post LT in former alcohol addicts, in addition to other factors such 
as pre-transplant nutritional status, use of medications and donor’s nutritional status.  
HYPOTHESIS EVALUATION 
Our hypothesis is based on four different assumptions regarding the population of patients who receive 
transplantation for alcohol liver disease:  
1) The prevalence of alcohol addiction decreases, while the prevalence of food addiction increases, after LT.  
2) A significant part of the weight gain, obesity and metabolic syndrome after LT is attributable to the increased 
prevalence of food addiction after LT. 
3) The increased prevalence of food addiction or alcohol relapse after LT occurs in patients with specific 
psychobiological risk factors. 
4) In patients who display addictive behaviours post-LT, the level of insight with regard to the somatic and 
psychological consequences of alcohol use before LT predicts either the development of a food addiction or the 
resuming of their former alcohol addiction after LT. 
 We will review here the pros and cons in support of each of these assumptions before addressing the 
added value of our hypothesis to the theoretical framework of post-LT complications and potentially refined 
treatment strategies. We will also describe the potential operationalisations that will be necessary to test our 
hypothesis.  
1) In the specific population of patients transplanted for alcohol-induced liver disease, the prevalence of alcohol 
addiction decreases, while the prevalence of food addiction increases, after LT.  
To explain the fact that the risk of relapsing to alcohol use after LT is lower than it is in control populations that 
are treated for alcohol abuse [12], a number of hypotheses might be proposed. First, these patients do face a life-
threatening illness, and they receive better social support through improved medical follow-up. Additionally, and 
perhaps even more importantly, patients benefit from the sustained support of peers and health professionals. 
Both factors may interact to greatly contribute to subsequently diminishing the risk of alcohol relapse through 
improved motivation to stop alcohol use, improved perceived social support and improved insight with regard to 
the somatic and psychological consequences of alcohol addiction. Third, alcohol use after LT might be restricted 
by heavy social pressure because LT is a rare and costly procedure. Considering this hypothesis, former alcohol 
addicts who crave alcohol after LT might cope by switching to a more socially accepted or less stigmatised 
substance or behaviour that could produce similar rewarding effects, thereby increasing the risk for a potential 
addiction to another reinforcer.  
 In that context, highly palatable food might be a reinforcerof choice because it is widely available and 
not yet socially stigmatised or associated with liver cirrhosis in the way that alcohol or illicit drugs are, and it has 
similar neurobiological properties to alcohol and other drugs [17,22–24]. Both drug use and the intake of certain 
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foods (e.g., sugar) have been associated with alterations to the brain’s reward systems, including dopamineergic, 
opioidergic, cholinergic, serotoninergic, and GABAergic systems [20,25], an observation that, along with other 
neuro-imaging studies, has yielded to the concept of overlapping processes between food and drug cravings [22]. 
Multiple lines of research have also demonstrated that food-addicted and drug-addicted individuals share 
common alterations in brain circuitry, including impaired dopaminergic pathways [26–28] such as those that 
regulate the neuronal systems associated not only with reward sensitivity and incentive motivation but also with 
conditioning (memory/learning), impulse control (behavioural inhibition), stress reactivity, and interoceptive 
awareness [28]. More specifically, both ventral striatal (predominantly associated with reward and motivation) 
and dorsal striatal (associated with habits or stimulus response learning) networks were found to be involved in 
both drug addiction and food addiction [28]. Recent studies have reported similar patterns of neural activation in 
addiction-like eating behaviours and substance dependence [23,29]. Studies have found elevated activation of the 
reward circuitry (the amygdala, anterior cingulate cortex, medial orbitofrontal cortex, dorsolateral prefrontal 
cortex and caudate) in response to food-related cues associated with the reduced activation of inhibitory regions 
(lateral orbitofrontal cortex) in response to food intake [23]; these regions are the same neural substrates that are 
hypothesized to underlie drug addiction [23,29]. These results have been confirmed in animal studies, in which 
the consumption of sugar-rich foods or drinks is associated with the release of endorphins and dopamine within 
the nucleus accumbens, akin to some drugs of abuse such as alcohol [30]. Not only does exposure to highly 
palatable food trigger neurobiological responses that are, at least qualitatively, similar to those of addictive drugs 
but both preclinical and clinical research has demonstrated that sugary and salty foods both induce withdrawal 
[17], which, at least for sugar, is associated with an imbalance in the acetylcholine and dopamine systems in the 
same manner as has been shown for opiate withdrawal [22].  
 Our hypothesis of an increased risk of food addiction in former alcohol addicts also stems from the 
clinical observation that former drug addicts who maintain abstinence display an increased preference for 
sweetness and tend to develop sugar addiction [30,31]. Former drug addicts also report significant weight gain 
during abstinence [31,32]. Some other studies conducted in patients treated for a substance use disorder found 
that abstinence from alcohol use was associated with significant weight gain, increase in BMI [33] and incidence 
of bulimia [34], suggesting higher food intake and potentially higher risk for food addiction after alcohol 
abstinence. In addition, when previous eating behaviour was restricted by bariatric surgery in patients who were 
obese – which is highly comorbid with food addiction [19] – alcohol use disorders increased [21]. Because this 
latter study suggests that a transfer from preoperative food addiction to postoperative alcohol addiction is 
possible, we can also assume that a transfer is also possible from preoperative alcohol addiction to postoperative 
food addiction in a subpopulation of vulnerable individuals. 
 Altogether, these data suggest close inter-relationships between food and alcohol addiction in that a 
decrease in one addiction is frequently associated with an increase in the other. However, the mechanisms by 
which the switch from one to the other occurs and the potential risk factors that might account for the switch 
remain to be established. Future studies should also take into account potential confounding factors to determine 
that these two observations are causally related. 
 
2) A significant part of the weight gain, obesity and metabolic syndrome after LT is attributable to the increased 
prevalence of food addiction after LT. 
We also hypothesise that significant proportions of the weight gain, obesity and metabolic syndrome 
that follow LT could be causally explained by the increased prevalence of food addiction after LT. Although no 
longitudinal studies have demonstrated that food addiction directly causes weight gain and obesity, perhaps 
because the clinical definition of food addiction is very recent, cross-sectional studies have demonstrated that 
food addiction is highly prevalent among obese patients [18,19]. Similarly, loss of control over eating – which is 
a key symptom of food addiction – predicted subsequent excessive weight gain among children and adolescents 
[35]. There is also some evidence that loss of control over eating in childhood is associated with both the 
subsequent development of components of metabolic syndrome and later overweight and obesity [35,36]. 
 Because obesity is a complex, multifactorial disease [37], other factors in addition to preoperative 
alcohol addiction could explain part of its increased prevalence following LT in former alcohol addicts. In liver-
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transplanted patients, intake of specific foods might also be facilitated by some of the medications that are 
frequently used after LT, such as steroids, which contribute to weight gain either through enhanced appetite 
(direct effect on food intake) or by stimulating the intake of sweet and high-fat foods (which could have an 
indirect effect on food intake through compulsive eating behaviour) [9]. Tobacco withdrawal is another factor 
that has often been associated with weight gain [38], but no studies have investigated this hypothesis in the 
specific population of liver-transplanted patients. 
 To explain the higher risk of obesity and metabolic syndrome after LT in former alcohol addicts, the 
impact of altering some metabolic functions consecutive to alcohol consumption could also be considered. 
Continuous or transient effects of alcohol on the autonomic nervous system and on the transport and metabolism 
of glucose might indeed be related to an increased concentration of glucose and triglycerides and high blood 
pressure, leading to higher risk of metabolic syndrome [39]. Leptin, a hormone implicated in regulating appetite, 
body weight and energy homeostasis, was found to be elevated in alcohol-dependent patients, and LT-associated 
alcohol abstinence may alter the function of this peptide thereby influencing the development of metabolic 
syndrome [39]. Although none of these factors alone can explain the higher risk of metabolic syndrome in this 
population, future studies should assess all of these possible risk factors for obesity in addition to those 
mentioned in our food addiction hypothesis.    
3) The increased prevalence of food addiction or alcohol relapse after LT occurs in patients with specific 
psychobiological risk factors. 
To explain the increased risk of these addictions, we will first discuss the risk factors that are typically 
shared among a wide range of addictions, including alcohol and food addiction, and then the factors that are 
more specific to a given addiction. Among these shared risk factors, some psychobiological factors might be 
associated with both food and alcohol addiction given that overlaps between binge eating and binge drinking 
have been demonstrated. These risk factors might include certain executive dysfunctions that are shared between 
binge eating and binge drinking, such as impaired cognitive flexibility or shifting attention [40,41] and some 
psychiatric comorbidities such as mood disorders, anxiety disorders [42,43], and attention deficit hyperactivity 
disorder [44,45]. Shared risk factors also include some stable personality features such as high neuroticism, low 
agreeableness, and low conscientiousness [46] (as well as high impulsivity [46,47]) that binge eating and binge 
drinking also share. We can thus assume that having such a personality and/or psychiatric profile would lead to a 
higher risk of post-transplant food/alcohol addiction. To our knowledge, no studies to date have assessed these 
dimensions in an integrative framework as potential risk factors for alcohol or food addiction in liver-
transplanted patients as well as in the overall population. Among the potential genetic risk factors, variants of the 
D2 dopamine receptor gene could be considered following the fact that Blum et al. hypothesised that the 
substitution of food addiction for other dependencies such as alcohol might be attributable to a specific reward 
deficiency syndrome (indeed, a core component of addiction) that has common genetic determinants such as 
variants of the D2 dopamine receptor gene, especially the DRD2 A1 allele [22]. 
 Although food addiction and alcohol addiction do share some common risk factors, different risk 
factors might also be implicated specifically in the development of either food or alcohol addiction. Not all 
patients who abstain from alcohol use will eventually develop food addiction, and we might also assume that 
some factors may play a protective role against one addiction or the other. As demonstrated by Volkow, 
although eating craved foods and drug addiction both activate the reward circuitry that involves dopaminergic 
pathways, these actions activate these pathways in different ways [48]. Food addiction affects the reward 
circuitry through endogenous opioids and cannabinoids, whereas drugs affect the same circuitry through direct 
effects on dopaminergic neurons or indirectly via other neurotransmitters [49]. In addition, the neurobiological 
regulation of feeding is much more complex than the regulation of drug intake because food consumption is 
controlled not only by reward but also by multiple peripheral, endocrine and central factors beyond those that 
participate in reward [48]. In line with this hypothesis, current studies indicate more widespread abnormalities in 
obesity and eating disorders than in drug addictions.  
 One interesting hypothesis comes from animal research, which has demonstrated that orexins are 
involved in motivation for drug use as well as natural rewards [50–53], providing an interesting theoretical 
framework whereby the underpinnings of compulsive alcohol use may facilitate the emergence of compulsive 
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food intake in previously alcohol-dependent patients after LT. Indeed, administration of orexins has been shown 
to stimulate food consumption [54]. In self-administration studies, the orexin 1 receptor antagonist SB-334867 
attenuated instrumental responses for high-fat pellets, sucrose pellets and ethanol but not cocaine, demonstrating 
that signalling at orexin receptors is necessary for mediating the reinforcing properties of specific rewards [51]. If 
altering the orexinergic system and orexin-dependent plasticity processes that sub-serve alcohol intake may 
facilitate the development of aberrant food intake under abstinence [51], further investigation is warranted to 
determine whether the function or dysfunction of the orexin system may contribute to the overeating associated 
with obesity in former alcoholics with LT. Similarly, alcohol-associated recruitment of the stress system in rats, 
including the activation of corticotropin releasing factor receptor 1 (CRF-R1) within the cortico-striatal circuitry 
may provide a long-lasting substrate to individual vulnerability to relapse to compulsive behaviours after stress 
[55,56]. 
As another example of a potential difference in terms of risk factors, alterations in the medial temporal 
and superior frontal regions that are functionally connected with the dorsal striatum could also be studied further 
given that they are associated with a greater vulnerability to obesity and eating disorders than to drug addictions 
[57]. Future studies should assess factors that could play either a protective or a vulnerability role in influencing 
relapse to either alcohol intake or food addiction. 
4) In patients who display addictive behaviours post-LT, the level of insight with regard to the somatic and 
psychological consequences of alcohol use before LT predicts either the development of a food addiction or the 
resuming of their former alcohol addiction after LT 
 In addition to the risk factors that are either common to both food and alcohol addiction or specific to a 
given addiction, the dimension of insight should also be considered. In patients who do either relapse to alcohol 
use or develop food addiction after LT, we hypothesise here that an increased prevalence of alcohol addiction 
after LT occurs more frequently in a specific subpopulation that is characterised by little insight into the cause of 
the liver failure, namely, alcohol addiction (see Figure 1).  
The concept of insight refers here to the ability to recognise one’s own mental illness, with its causes 
and consequences [58], and refers to patients’ awareness and understanding of their attitudes, feelings, 
behaviours, and symptoms. Insight encompasses two different dimensions: symptom insight, the patient’s 
awareness of his symptoms, and attribution, which refers to how the patient causally attributes his illness [59]. 
Because lower insight into alcohol addiction has been associated with poorer outcomes following treatment [60], 
we assume that in patients who develop either food or alcohol addiction after LT, those who attribute their liver 
disease to a cause other than alcohol (low attribution) are at higher risk of relapsing to alcohol addiction than are 
patients with non-impaired insight (Figure 1). More specifically, patients who receive transplantation for alcohol 
liver disease may be at higher risk than other patients of developing a post-transplant food addiction because 
they may, under the peer and moral pressure associated with LT, manage their addiction by displacing the object 
of their craving from alcohol to food, the latter being considered a non-dangerous source of reward relative to 
the former (i.e., addiction transfer). We suggest here that insight with regard to the somatic and psychological 
consequences of alcohol should be addressed specifically in addition to the other well-known post-LT risk 
factors for alcohol relapse that we have previously discussed.  
 
HOW SHOULD WE TEST OUR HYPOTHESES? 
The best approach to testing this model appears to be one that relies on a translational design. Indeed, in addition 
to the clinical usefulness of human models, animal models allow for a direct causal understanding of the 
neurobiological and pharmacological factors that cannot be assessed in humans for obvious ethical reasons. 
Additionally, preclinical studies allow for a complete longitudinal approach that gives insights into the 
contribution of premorbid risk factors to the switch from alcohol addiction to food addiction, as illustrated in the 
addiction field [61,62].  
 In human studies, we will first investigate, within a longitudinal study, both pre- and post-LT alcohol 
addiction and food addiction over a period of at least three years to screen for a sufficient number of patients 
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who have developed an addiction after LT. To test the hypothesis that both decreases in alcohol use disorders 
and increases in food addiction are causally related, we will regularly (once a year) assess both disorders using 
appropriate and reliable measures: food addiction will be assessed using the Yale Food Addiction Scale, the gold 
standard for such assessments [15,63]; alcohol addiction will be assessed using semi-structured interviews based 
on DSM-5 criteria. Because it is often difficult for patients to tell the transplantation team that they have relapsed 
[64] and because medical record reviews alone greatly underestimate alcohol relapse rates [6], we will establish 
whether relapse indeed occurred using repeated measurements with complementary methods, including a patient 
self-report, a collateral report, and biological measures [6,65]. We will also separate the study staff from the 
transplantation staff to keep notifications of alcohol or drug use confidential within the study [64]. 
 To demonstrate that the increased prevalence of obesity, weight gain and metabolic syndrome after LT 
could be causally related to food addiction, we will assess not only body mass index but also the prevalence of 
diabetes, dyslipidemia and hypertension. If this association is confirmed, we will then search for explanations 
that might account for this significant association. To demonstrate that this switch occurs in a vulnerable 
subpopulation, we will jointly investigate the neurobiological, psychiatric and psychological factors that are 
typically associated with both food addiction and alcohol addiction, at both the clinical and preclinical levels. 
These factors include personality dimensions (which we will measure using the Big Five Inventory, a brief and 
reliable measure of the five common personality dimensions) [66,67], personality traits (such as impulsivity, 
which can be measured for example using the Barratt Impulsiveness Scale) [68] and psychiatric disorders 
(attention deficit hyperactivity disorder, major depression, anxiety disorders, personality disorders, which can be 
measured using clinical interviews based on DSM criteria) [1].  
 However, in human studies, for obvious ethical reasons, it is difficult to disentangle LT’s contribution 
to metabolic regulation from the processes that depend on the pharmacological treatments that are associated 
with LT, namely, immunosuppressive drugs such as cyclosporine. Indeed, the latter have been suggested to 
potentially contribute to post-LT obesity, MS and lower rates of alcohol relapse [8,14,69]. We will therefore use 
preclinical models in rats with great heuristic value with regard to habitual and compulsive alcohol [70] and food 
seeking and taking [71] to identify the neurobiological substrates of the effect of cyclosporine treatment on 
relapse to alcohol or food-seeking behaviour and the potential switch from alcohol. Thus, we propose to address 
these issues in a preclinical model of habitual and compulsive alcohol and food seeking. Animal studies will also 
be helpful in studying the polymorphisms in orexin genes that could contribute to alcohol relapse or food 
addiction after LT.  
 Finally, we will also implement longitudinal studies in rats that aim at identifying whether specific 
behavioural markers such as novelty seeking, impulsivity, decision making, sweetness preference, sign tracking, 
behavioural flexibility and anxiety [61,72–75] contribute to an increased propensity to switch from alcohol to 
compulsive food seeking with or without cyclosporine treatment following self-abstinence triggered by repeated 
adverse consequences related to alcohol seeking [76]. 
 This combination of a clinical and preclinical model will provide the scientific community with a new 
post-LT prognostic approach, thereby unlocking both a scientific and technical barrier: better insight into the 
psychological and biological dimensions that are associated with post-transplant food addiction, metabolic 
syndrome and obesity and a preclinical model of the switch from a previous addiction to food addiction. The 
model has clear medical and translational implications because it should provide new avenues for treating the 
primary post-LT impairments, namely obesity, metabolic syndrome, food addiction and alcohol addiction.  
 
CONSEQUENCES OF THE HYPOTHESIS: DISCUSSION 
Provided that it is confirmed, the present hypothesis may yield to a novel treatment strategy for helping 
some patients benefit from LT, as well as to new avenues for future research not only in liver-transplanted 
patients but also in patients who are followed up for alcohol addiction.  
 Implications for liver-transplanted patients include the fact that patients with a history of pre-transplant 
alcohol addiction should be systematically screened after LT for food addiction and followed up for subsequent 
risk of obesity and metabolic syndrome. These patients should also be screened for psychiatric disorders both pre 
 9 of 13 
and post LT. A subpopulation of vulnerable individuals who develop post-LT obesity or metabolic syndrome 
could also be referred to addiction units in order to screen for and treat food addiction. Interventions that target 
risk factors for both alcohol and food addiction in the pre- and post-transplant periods could also reduce the 
prevalence of these two disorders after LT. Such interventions are critical because they could not only improve 
survival, comorbidities and health-related quality of life after LT but also help to address the critical shortage of 
donor organs and increase public willingness to donate.  
 Such an integrative assessment would enable the early recognition of food addiction and alcohol 
addiction and their risk factors, as well as early screening for psychiatric comorbidities that could potentially 
diminish quality of life if left untreated. These studies could help to build a simple and practical tool for 
clinicians that could include assessing the specific pre- and post-LT psychiatric and personality dimensions that 
are associated with post-LT food and alcohol addiction and poorer outcomes. This assessment is also a 
preliminary step before effective psychopharmacological and psychotherapeutic strategies that target these 
specific risk factors can be tested. Given that the drugs used to treat both of these disorders are primarily 
metabolised by the liver, studies that focus on the efficacy and side effects of psychopharmacological strategies 
should take into account the prominent concern about safety and overdosing in this population.  
Finally, the dimension of insight should be systematically assessed after LT so that psychotherapeutic 
interventions that target insight itself or the psychopathological factors associated with it might be undertaken. If 
low insight is confirmed to be a risk factor for subsequent alcohol addiction, psychotherapeutic strategies such as 
motivational interviewing could be effective and should be tested in these populations. Such an approach finally 
aims to improve patients’ survival, outcomes and quality of life following LT. 
 Our addiction transfer model could also be tested and generalised for patients in the overall population 
who are treated for alcohol addiction because current studies suggest that patients who stop alcohol use are at 
higher risk of developing food addiction, thereby leading to an increased risk of obesity and metabolic 
syndrome. Investigation of our model might also help discover neurobiological, psychiatric and psychological 
risk factors for both alcohol addiction and food addiction. These studies would help us improve our 
understanding of the links between alcohol addiction, food addiction and obesity and, ultimately, to developing 
more efficient therapeutic strategies for these patients. Future studies should also determine whether our 
addiction transfer model could also be extrapolated to other patients; it could, for example, explain why some 
patients who are treated for food addiction develop alcohol addiction after treatment (i.e., in a subpopulation of 
bariatric surgery patients), why patients who are treated for alcohol addiction may be at higher risk of switching, 
and this model could even explain addiction transfers between alcohol and other addictions (i.e., other drug and 
behavioural addictions).  
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Figure 1. In patients who either relapse to alcohol or develop food addiction after LT, low insight predicts 
an increased propensity to relapse to alcohol addiction, whereas high insight relapse predicts an increased 
propensity to develop food addiction. 
 
FIGURE LEGEND:  
This figure differentiates between (1) patients who relapse to alcohol or develop food addiction after LT (top of 
the figure) and (2) patients who do not (bottom of the figure). As illustrated in the left part of the figure, the first 
population is more likely to have a high risk of relapse (as assessed by the combination of psychobiological 
factors that we have previously discussed in the paper), whereas the second population is more likely to have a 
low risk of relapse (as assessed by the same combination of psychobiological factors). 
In patients who develop addiction after LT (top of the figure), we hypothesise that the level of insight with 
regard to the somatic and psychological consequences of alcohol might predict either alcohol relapse or the 
development of food addiction after LT. In this population and after LT, we hypothesise that patients with low 
insight (e.g., “my liver failure has nothing to do with my drinking behaviour”) are at higher risk for relapsing to 
alcohol addiction, whereas patients with high insight (e.g., “I recognise that my drinking behaviour is 
responsible for my liver failure”) are at higher risk for developing food addiction. Before the diagnosis of liver 
failure (LF) and LT, these patients might have experienced a different type of insight that was more difficult to 
assess because it was affected by LF-induced cognitive deficits. 
LF: Liver Failure.  
LT: Liver Transplantation. 
 
